Document Type

Poster

Publication Date

3-30-2017

Funding Agency

Institute for Antiviral Research

Abstract

Rift Valley fever (RFV) is a mosquito-borne disease, endemic to Africa, and known to cause abortion in animals and hemorrhagic fever in humans. All enveloped viruses require the fusion of viral membranes with cellular membranes to enter into and replicate inside the host cell. These viruses have a universal objective: find the cell receptors that match the viral attachment proteins and use those to gain access to the cell membrane. The use of aUY11, a monosaccharide (sugar)-based compound, has previously shown to effectively use a biophysical approach in the inhibition of viral fusion of other enveloped viruses1. In this study, we attempt to use aUY11 to inhibit the fusion of Rift Valley fever virus (RVFV) in vitro as a primary step in the creation of an FDA-approved vaccination for humans and animals to protect against often-lethal RVFV infection. We show here that aUY11 inhibits viral replication in Vero 76 cells and therefore has potential as an RVFV vaccine.

Included in

Biology Commons

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.